TG Therapeutics, Inc. (NASDAQ:TGTX – Get Rating)’s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.83 and traded as high as $6.86. TG Therapeutics shares last traded at $6.59, with a volume of 1,447,417 shares trading hands.
Analysts Set New Price Targets
TGTX has been the topic of a number of recent analyst reports. StockNews.com raised TG Therapeutics to a “sell” rating in a research report on Friday, June 17th. B. Riley reduced their price target on shares of TG Therapeutics from $23.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 13th. Three investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $21.25.
TG Therapeutics Trading Down 2.1 %
The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 0.53. The stock has a market cap of $957.36 million, a PE ratio of -3.05 and a beta of 2.19. The business’s fifty day moving average is $6.83 and its 200 day moving average is $6.83.
Institutional Inflows and Outflows
About TG Therapeutics
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.
- Get a free copy of the StockNews.com research report on TG Therapeutics (TGTX)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.